NASDAQ:NLNK NewLink Genetics (NLNK) Stock Price, News & Analysis → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Free NLNK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.41▼$2.7650-Day Range$0.89▼$14.1052-Week Range$0.82▼$3.60Volume12,386 shsAverage Volume547,540 shsMarket Capitalization$97.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get NewLink Genetics alerts: Email Address Ad InvestorPlaceYou’re invited: Biggest crypto event of 2024During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. About NewLink Genetics Stock (NASDAQ:NLNK)NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.Read More Ad InvestorPlaceYou’re invited: Biggest crypto event of 2024During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. NLNK Stock News HeadlinesMarch 20, 2024 | wsj.comNewlink Technology Inc.March 6, 2024 | markets.businessinsider.comHere's what Wall Street expects from NewLink Genetics's earnings reportApril 19, 2024 | InvestorPlace (Ad)You’re invited: Biggest crypto event of 2024During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.December 19, 2023 | investing.comNewlink Technology Inc (9600)October 27, 2023 | foxnews.comSuicide and genetics: Study identifies 12 DNA variations that could increase the riskAugust 23, 2023 | forbes.comGenetic Testing Before Pregnancy: What You Need To KnowJune 28, 2023 | thestreet.comWhy NewLink Genetics (NLNK) Stock Is Gaining TodayMay 23, 2023 | fool.comDigimarc (NASDAQ: DMRC)April 19, 2024 | InvestorPlace (Ad)You’re invited: Biggest crypto event of 2024During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.February 15, 2023 | thestreet.comTrade Ebola Stocks? Sure, But Don't Bet on Big Business OpportunityJanuary 17, 2023 | dailymail.co.ukWill parents take up a DNA test to spot rare diseases? Expert predicts genetic codes of babies could be read by the NHS in as little as five yearsJanuary 14, 2023 | thestreet.comJumpstart ASCO '15 With This Quick List of Hot Research AbstractsJanuary 14, 2023 | thestreet.comCorbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed PositiveAugust 3, 2021 | markets.businessinsider.comHere's what Wall Street expects from NewLink Genetics's earningsSee More Headlines Receive NLNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2019Today4/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:NLNK CUSIP65151110 CIK1126234 Webwww.newlinkgenetics.com Phone515-296-5555FaxN/AEmployees55Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,990,000.00 Net Margins-4,592.84% Pretax MarginN/A Return on Equity-41.50% Return on Assets-33.95% Debt Debt-to-Equity RatioN/A Current Ratio7.98 Quick Ratio7.98 Sales & Book Value Annual Sales$940,000.00 Price / Sales104.04 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book1.24Miscellaneous Outstanding Shares37,328,000Free FloatN/AMarket Cap$97.80 million OptionableNot Optionable Beta1.17 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Charles J. Link Jr. (Age 60)Co-Founder, Chairman, CEO & Chief Scientific Officer Mr. Nicholas N. Vahanian (Age 52)Co-Founder, Pres, Chief Medical Officer & Director Dr. Eugene P. Kennedy M.D. (Age 50)FACS, Chief Medical Officer Mr. Brian Wiley (Age 51)Chief Commercial Officer Mr. Carl W. Langren (Age 64)CFO & Principal Accounting Officer Key CompetitorsEmergent BioSolutionsNYSE:EBSBolt BiotherapeuticsNASDAQ:BOLTFortress BiotechNASDAQ:FBIORegulus TherapeuticsNASDAQ:RGLSRigel PharmaceuticalsNASDAQ:RIGLView All Competitors NLNK Stock Analysis - Frequently Asked Questions How were NewLink Genetics' earnings last quarter? NewLink Genetics Corp (NASDAQ:NLNK) posted its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($0.27) EPS for the quarter, meeting analysts' consensus estimates of ($0.27). The biotechnology company earned $0.25 million during the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative trailing twelve-month return on equity of 41.50%. What other stocks do shareholders of NewLink Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Novavax (NVAX), SunPower (SPWR), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Cara Therapeutics (CARA) and Gilead Sciences (GILD). This page (NASDAQ:NLNK) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceUrgent alert: open this for a huge profit potentialTimothy SykesHow Biden has already won 2024Porter & CompanyOptions trading has suddenly become more reliable.Eagle Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewLink Genetics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.